CORDIS
EU research results

CORDIS

English EN
Big Data 4 Better Hearts - Sofia ref.: 116074

Big Data 4 Better Hearts - Sofia ref.: 116074

Objective

Despite remarkable progress in the management of cardiovascular disease (CVD), major unmet needs remain with regard to mortality, hospitalisations, quality of life (QoL), healthcare expenditures and productivity. Acute coronary syndrome (ACS), atrial fibrillation (AF) and heart failure (HF) are major and growing components of the global CVD burden. Optimal management of these conditions is complicated by their complex aetiology and heterogeneous prognoses. Poor definition at the molecular level and co/multi-morbidities form major challenges for the development and delivery of targeted treatments. This renders response to therapy unpredictable, with large inter-individual variation and, importantly, small or undetectable treatment effects in large trials of unselected patients.

Today’s treatment guidelines still reflect the scientific constraints of an earlier era where clinical markers to guide therapy are limited to conventional risk factors and end-organ damage, and where the main endpoint in clinical trials is patient death. Hence, drug development pipelines from early target validation through to late post-marketing work have proven to be slow, expensive and high-risk: the chance of eventual approval for a CVD drug candidate in Phase I trials is 7%, the lowest of any disease category (shared with oncology) 2. Moreover, tolerability of medication and adherence to treatment show wide variations. There is thus a need for better definition of these diseases, their markers and endpoints (including better segmentation of current heterogeneous patient groups acknowledging underlying mechanisms and comorbidities) and of their outcomes/prognoses (including functional capacity and quality of life [QoL]).

BigData@Heart’s ultimate goal is to develop a Big Data--driven translational research platform of unparalleled scale and phenotypic resolution in order to deliver clinically relevant disease phenotypes, scalable insights from real-world evidence and insights driving
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Address

Heidelberglaan 100
3584 Cx Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 4 047 075

Participants (18)

Sort alphabetically

Sort by EU Contribution

Expand all

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 929 375

SOCIETE EUROPEENNE DE CARDIOLOGIE

France

EU Contribution

€ 874 688

EUROPEAN HEART NETWORK AISBL

Belgium

EU Contribution

€ 150 800

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 1 136 250

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 391 845

INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT INC.

United States

EU Contribution

€ 319 375

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA

Spain

EU Contribution

€ 386 250

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 200 000

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Germany

EU Contribution

€ 386 250

STICHTING MLC FOUNDATION

Netherlands

EU Contribution

€ 116 812

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 200 000

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 200 000

Bayer

Germany

NOVARTIS PHARMA AG

Switzerland

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

France

SOMALOGIC INC

United States

VIFOR (INTERNATIONAL) AG

Switzerland

THE HYVE BV

Netherlands

EU Contribution

€ 326 250

Project information

Grant agreement ID: 116074

Status

Ongoing project

  • Start date

    1 March 2017

  • End date

    28 February 2022

Funded under:

H2020-EU.3.1.

  • Overall budget:

    € 19 398 970

  • EU contribution

    € 9 664 970

Coordinated by:

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands